Elevated pretreatment serum concentration of YKL-40: An independent prognostic biomarker for poor survival in patients with colorectal cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elevated pretreatment serum concentration of YKL-40: An independent prognostic biomarker for poor survival in patients with colorectal cancer
Authors
Keywords
Colorectal cancer, YKL-40, Survival
Journal
MEDICAL ONCOLOGY
Volume 31, Issue 8, Pages -
Publisher
Springer Nature
Online
2014-07-05
DOI
10.1007/s12032-014-0085-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study
- (2014) Line S. Tarpgaard et al. PLoS One
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- High YKL-40 Serum Concentration Is Correlated with Prognosis of Chinese Patients with Breast Cancer
- (2012) Dong Wang et al. PLoS One
- Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation and other cancer markers
- (2011) R Shao et al. BRITISH JOURNAL OF CANCER
- Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
- (2011) K H Allin et al. BRITISH JOURNAL OF CANCER
- Plasma YKL-40 levels in healthy subjects from the general population
- (2011) Stig E. Bojesen et al. CLINICA CHIMICA ACTA
- The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure
- (2011) Marina Harutyunyan et al. IMMUNOBIOLOGY
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma
- (2011) Ralph A. Francescone et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children
- (2011) Ioannis Kyrgios et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A YKL-40-Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in Cancers
- (2011) M. Faibish et al. MOLECULAR CANCER THERAPEUTICS
- Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
- (2011) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Inhibitory Activity of YKL-40 in Mammary Epithelial Cell Differentiation and Polarization Induced by Lactogenic Hormones: A Role in Mammary Tissue Involution
- (2011) Steve Scully et al. PLoS One
- The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer
- (2010) L. Zou et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer
- (2010) Ina Thöm et al. CANCER
- Plasma YKL-40 and Total and Disease-Specific Mortality in the General Population
- (2010) J. S. Johansen et al. CLINICAL CHEMISTRY
- YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
- (2010) Nicolai A. Schultz et al. Cancers
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now